Posts Tagged ‘quote’

Quick comment on AI for pharma?

July 18, 2017

Please find the article at link:
https://www.pharma-iq.com/informatics/articles/is-big-pharma-really-on-cusp-of-ai-shake-out-0

Is big pharma really on cusp of AI shake-out?

By: Pharma IQ
Posted: 07/14/2017

QT:{{”

The promises of “disruptive technologies” have failed to live up to expectations in the past. For example, the development of ‘high throughput screening’ – a process that employs robotics to conduct millions of chemical, genetic and pharmacological tests in rapid time – in the 1990s failed to significantly reduce R&D inefficiencies and offered sporadic success rates.

“The major cost in drug R&D is last-phase clinical trials,” said Dr Mark Gerstein, professor of biomedical informatics at Yale University. “It is not clear whether AI can be as useful for these as it has been in target selection for the initial phases.”

“One of the first principles of data mining is that history is a good predictor of the future. AI has a track record of not living up to its expectations and therefore caution about how great its impact will be in the healthcare industry is now warranted.”
“}}

In Rural Oasis, Serpico Finds New Adversaries – NYTimes.com

July 14, 2017

In Rural Oasis, #Serpico Finds New Adversaries
http://www.NYTimes.com/2013/07/05/nyregion/for-serpico-who-fought-police-corruption-a-new-conflict-over-woodland.html Famous cop from the past protecting #trees from a McMansion developer

QT:{{”
“But now Mr. Serpico’s serenity has been broken and he finds himself battling a new nemesis. This time, it is not an entire agency, but a local developer and town officials who Mr. Serpico says have ignored his complaints; this time, it is not over issues like taking cash payments from drug dealers, but over the fate of some trees and the desecration of pristine woodland.

“It’s like fighting the system again,” Mr. Serpico said. “Here I’m trying to enjoy my tranquillity and I’m being dragged back into a world of corruption.”
“}}

Lame duck laureates

July 14, 2017

Lame duck laureates
http://www.Economist.com/blogs/freeexchange/2013/08/nobel-prize-economics Interesting #bibliometric analysis of Nobelists: their normalized citations peak at the prize

QT:{{”
“The authors count the number of citations for each Nobel
prize-winner, using a service provided by JSTOR, a digital library. They look at what happens to Nobel prize-winners before and after they win their prizes. The data span from 1930 to 2005. One of the problems facing the authors was that, in 2005, there were many more JSTOR articles than in 1930. Therefore, raw citation numbers were
standardised by the total number of articles published in that year. The authors call the standardised units “Arrows”, after Kenneth Arrow, the economist who won the prize in 1972.”
“}}

Germ-Free Mice | NIH Intramural Research Program

July 10, 2017

https://irp.nih.gov/catalyst/v19i4/germ-free-mice
QT:{{”
NIAID is home to one of the few facilities in the United States that houses so-called gnotobiotic mice. These mice are born in germ-free conditions, and investigators control the microbiota by inoculating the animals with specific microorganisms. The word “gnotobiotic” comes from the Greek words gnostos, for known, and bios, for life. “}}

A comprehensive review of genetic association studies. – PubMed – NCBI

July 10, 2017

https://www.ncbi.nlm.nih.gov/pubmed/11882781

QT:{{"
We find that over 600 positive associations between common gene variants and disease have been reported; these associations, if correct, would have tremendous importance for the prevention, prediction, and treatment of most common diseases. However, most reported associations are not robust: of the 166 putative associations which have been studied three or more times, only 6 have been consistently replicated.

"}}

US cancer institute to overhaul tumour cell lines

July 9, 2017

QT:{{"
“The NCI will continue to supply the NCI-60 cell lines to researchers, but will eventually refocus its drug screening on newer models. It is developing hundreds of ‘patient-derived xenografts’ (PDXs), which are created by implanting small chunks of human tumours into mice. There, the tumours grow in an environment that, although not human, better mimics their native environment”
"}}

Google’s Road Map to Global Domination

July 6, 2017

$GOOG’s Road Map to Global Domination
http://www.NYTimes.com/2013/12/15/magazine/googles-plan-for-global-domination-dont-ask-why-ask-where.html Old article but discussion on #opendata v closed maps still relevant

QT:{{”
“O’Reilly is more skeptical. “An open-hardware play broke the IBM monopoly, an open-software play broke the Microsoft monopoly, and eventually an open-data play will prevail,” O’Reilly admits, but he points out that those earlier cases were not instances of direct competition between rival companies. “It wasn’t a plug-compatible mainframe clone that dethroned IBM; it wasn’t a free operating system like Linux that dethroned Windows.” Rather, he says, “it was this toy, the personal computer, it was the global operating system that we call the Internet.”
”}}

Anti-ageing pill pushed as bona fide drug

July 4, 2017

QT:{{‘

“Current treatments for diseases related to ageing “just exchange one disease for another”, says physician Nir Barzilai of the Albert Einstein College of Medicine in New York. That is because people treated for one age-related disease often go on to die from another relatively soon thereafter. “What we want to show is that if we delay ageing, that’s the best way to delay disease.”

Barzilai and other researchers plan to test that notion in a clinical trial called Targeting Aging with Metformin, or TAME. They will give the drug metformin to thousands of people who already have one or two of three conditions — cancer, heart disease or cognitive impairment — or are at risk of them. People with type 2 diabetes cannot be enrolled because metformin is already used to treat that disease.
“}}
http://www.nature.com/news/anti-ageing-pill-pushed-as-bona-fide-drug-1.17769

AI for drug discovery – cyan

July 4, 2017

Make Pharma Great Again w. AI, by @mostafabenh
https://Medium.com/@mostafab/make-pharma-great-again-with-artificial-intelligence-some-challenges-50e91ea9988d Optimism-inducing Moore’s law in tech vs. #Eroom’s law for drugs

QT:{{”
Drug discovery is getting increasingly tough and expensive. Despite technological progress, the cost of developing a new drug doubles every nine years. That’s Eroom’s law of Pharma, which mirrors Moore’s law for computer performance.

….

Drugs are getting more expensive

In the tech industry, the situation is different. Optimism prevails. Tech is fueled by Moore’s law, the fact that computer performance is doubling every 18 months.

Moore’s law

This exponential progress keeps prices low. For example, Google gives away the use of its new TPU chip for free, for some scientific projects. Tech companies are more generous due to their feeling of abundance. How can Tech help Pharma, especially at a time of expansion for Artificial Intelligence?
“}}

‘Make Pharma Great Again with Artificial Intelligence: some Challenges’

https://medium.com/@mostafab/make-pharma-great-again-with-artificial-intelligence-some-challenges-50e91ea9988d

Clues from the resilient

July 4, 2017

Clues from the resilient
http://www.ScienceMag.org/content/344/6187/970.full Potential 2nd site mutations that neutralize #Mendelian-disease mutations

QT:{{”
“For 127 catastrophic Mendelian diseases (those caused by a single gene such as cystic fibrosis and ataxia-telangiectasia), there are presently 164 genes harboring 685 known recurrent variants that are highly penetrant and causal for deleterious traits, most typically manifesting in individuals before the age of 18 (). …For common diseases, the observed small effect sizes of individual gene variants limit diagnostic potential, and given that most variants identified have an unclear function, how to target the corresponding gene for therapeutic intervention is typically unclear. For rarer Mendelian disorders, although genetics directly implicate a specific gene in a disease, a majority of such cases relate to loss-of-function mutations. Designing small molecules to fix the corresponding broken protein has proven difficult….
The prominent role of second-site mutations and environmental factors that enable resistance to (or buffer against) disease traits has been well established in a multitude of model organisms from yeast to mice (–). Screening for second-site mutations in “resilient” individuals that prevent disease-causing alleles from manifesting their effects could identify targets to which drugs would be designed to disrupt their function, as opposed to targeting the disease-causing gene directly. Genetic studies examining seemingly healthy people have revealed, for example, rare mutations in chemokine (C-C motif) receptor type 5 (the co-receptor for human immunodeficiency virus) that block HIV infection (), and secondary mutations in fetal globin genes that modify the severity of sickle cell disease by buffering primary mutations in β-globin genes ()
“}}